Anne C. Goldberg

Anne C. Goldberg

Auto-generated profile, based on publicly available information

Anne C. Goldberg

Division of Endocrinology, Metabolism and Lipid Research, Washington University School of Medicine, St. Louis, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2021 in Cardiovascular Drugs and Therapy
Verified
Journal Article
Open access
PDF file
CBChristie M. Ballantyne
Christie M. Ballantyne
HBHarold Bays
Harold Bays
Alberico Luigi Catapano‌Alberico Luigi Catapano‌
Alberico Luigi Catapano‌
AGAnne Goldberg
Anne Goldberg
KRKausik K. Ray
Kausik K. Ray
JSJoseph J Saseen
Joseph J Saseen
Many patients do not achieve optimal low-density lipoprotein cholesterol (LDL-C) levels with statins alone; others are unable to tolerate statin therapy. Additional non-statin treatment options including ezetimibe, proprotein convertase subtilisin/kexin type 9 inhibitors, and bile acid sequestrants are often necessary to further reduce the risk of atherosclerotic cardiovascular disease. This review provides practical guidance as to the use of bempedoic acid to lower LDL-C and includes direction as to which patients may benefit and advice for safety monitoring during treatment. Bempedoic acid, a new class of agent, is a prodrug converted to bempedoyl-CoA by very long-chain acyl-CoA synthetase 1, an enzyme with high expression in the liver but that is undetectable in the skeletal muscle. Bempedoic acid inhibits the enzyme adenosine triphosphate (ATP)-citrate lyase, which lies two steps upstream from β-hydroxy β-methylglutaryl-CoA reductase in the cholesterol biosynthesis pathway. In clinical trials conducted in patients with or at risk for atherosclerotic cardiovascular disease or familial heterozygous hypercholesterolemia, bempedoic acid in combination with statins and/or ezetimibe significantly reduced LDL-C, apolipoprotein B, and high-sensitivity C-reactive protein compared with placebo. Bempedoic acid is generally well tolerated with no clinically meaningful increase in muscle-related symptoms relative to placebo, even in patients taking maximally tolerated statins. A small increase in serum uric acid (mean increase 0.8 mg/dL) is the most noteworthy adverse effect. Bempedoic acid provides an effective and generally well-tolerated medication to further reduce LDL-C in patients taking maximally tolerated statins or manage LDL-C levels in those who are unable to take statins. The potential for a reduced incidence of major cardiovascular events with bempedoic acid is being investigated in the CLEAR Outcomes trial, with results expected in 2023.

29 January 2026 in Journal of Clinical Lipidology
Verified
Journal Article
Open access
ZAZahid Ahmad
Zahid Ahmad
AAAnandita Agarwala
Anandita Agarwala
MCMarina Cuchel
Marina Cuchel
PDP. Barton Duell
P. Barton Duell
RHRobert Hegele
Robert Hegele
AGAnne C. Goldberg
Anne C. Goldberg
Familial hypercholesterolemia (FH) is a common genetic disorder characterized by lifelong elevated low-density lipoprotein cholesterol (LDL-C), leading to a high risk of early onset atherosclerotic cardiovascular disease (ASCVD). This document provides an update to the National Lipid Association's 2011 clinical guidance, summarizing the remarkable progress in the field. With a global prevalence of approximately 1 in 311, FH remains severely underdiagnosed. This guidance reviews current diagnostic criteria, including the expanding role of genetic testing to complement diagnosis and to facilitate cascade screening, and emphasizes a thorough differential diagnosis. It provides recommendations for universal pediatric screening and systematic cascade screening in families to improve detection. Management strategies include intensified LDL-C treatment goals for both primary and secondary prevention of ASCVD. A stepwise approach to optimal therapy is outlined, beginning with lifestyle interventions and pharmacotherapy with maximally tolerated statins and ezetimibe. This update incorporates newer agents, including proprotein convertase subtilisin/kexin type 9 inhibitors and bempedoic acid. Additional therapies, such as lomitapide and evinacumab for homozygous FH and lipoprotein apheresis for heterozygous and homozygous FH, are discussed. Further topics include cardiovascular imaging for risk stratification, management in specific populations and circumstances, such as planning for and during pregnancy and in pediatrics, and recognition of health disparities. This guidance equips clinicians with evidence-based strategies to improve the identification and care of patients with FH, ultimately reducing the high morbidity and mortality associated with this condition.

1 July 2020 in Journal of Lipid Research
Verified
Journal Article
Open access
PDF file
LPLinda Peterson
Linda Peterson
XJXuntian Jiang
Xuntian Jiang
LCLing Chen
Ling Chen
AGAnne C. Goldberg
Anne C. Goldberg
MFMarsha S. Farmer
Marsha S. Farmer
JSJean E. Schaffer
Jean E. Schaffer
Linda R. Peterson, Xuntian Jiang, Ling Chen, Anne C. Goldberg, Marsha S. Farmer, Daniel S. Ory, Jean E. Schaffer

11 January 2024 in Journal of Clinical Lipidology
Verified
Journal Article
Open access
PDP. Barton Duell
P. Barton Duell
MBMaciej Banach
Maciej Banach
Alberico Luigi Catapano‌Alberico Luigi Catapano‌
Alberico Luigi Catapano‌
ULUlrich Laufs
Ulrich Laufs
GMG B John Mancini
G B John Mancini
AGAnne C. Goldberg
Anne C. Goldberg
Background: Patients with heterozygous familial hypercholesterolemia (HeFH) often cannot reach guideline-recommended low-density lipoprotein cholesterol (LDL-C) goals despite multidrug therapy. Objective: To evaluate the efficacy and safety of bempedoic acid as an add-on therapy for lowering LDL-C in patients with HeFH. Methods: Pooled data from two 52-week phase 3 clinical trials of patients with atherosclerotic cardiovascular disease and/or HeFH receiving maximally tolerated statin therapy (randomized 2:1 to bempedoic acid or placebo) were analyzed by HeFH status. Endpoints included changes from baseline to week 12 (and up to week 52) in LDL-C and other lipid parameters, achievement of LDL-C goals, and safety. Results: A total of 217 (bempedoic acid, 146; placebo, 71) patients with HeFH and 2,792 (bempedoic acid, 1,864; placebo, 928) without HeFH were included (mean baseline LDL-C, 172.8 mg/dL and 102.6 mg/dL, respectively). Bempedoic acid significantly lowered LDL-C at week 12 vs. placebo regardless of HeFH status (with HeFH, -21.2%; without HeFH, -18.2% [both P<0.0001]). Bempedoic acid significantly reduced other lipid parameters and high-sensitivity C-reactive protein vs. placebo regardless of HeFH status (all P <= 0.01). Among patients with HeFH treated with bempedoic acid, 32% and 27% achieved LDL-C <100 mg/dL at weeks 12 and 52, respectively. Overall treatment-emergent adverse event incidence was comparable across all four groups (74.7-77.5%). Conclusion: Bempedoic acid significantly lowered LDL-C levels vs. placebo and was generally well tolerated in all patients, with no new safety findings in patients with HeFH, despite more intensive lipid-lowering therapy in patients with vs. without HeFH.

1 October 2010 in American Heart Journal
Verified
Journal Article
Closed access
PJPeter H. Jones
Peter H. Jones
AGAnne C. Goldberg
Anne C. Goldberg
HKHoward R. Knapp
Howard R. Knapp
MKMaureen T. Kelly
Maureen T. Kelly
CSCarolyn M. Setze
Carolyn M. Setze
DSDarryl J. Sleep
Darryl J. Sleep

6 August 2011 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
PDF file
ASA. F. H. Stalenhoef
A. F. H. Stalenhoef
MDM. H. Davidson
M. H. Davidson
JRJ. G. Robinson
J. G. Robinson
TBT. Burgess
T. Burgess
RDR. Duttlinger‐Maddux
R. Duttlinger‐Maddux
HBHarold Bays
Harold Bays